Autoimmune Axonal Evaluation
Test in Focus
Mayo Clinic Laboratories utilizes a comprehensive, phenotypic testing approach to evaluate for antibodies associated with autoimmune axonal neuropathy. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Divyanshu Dubey, M.B.B.S., discusses the serological panel, which uses multiple methodologies to detect for nine distinct antibodies.
“All of the antibodies included in this panel are of significant relevance to patients with neuropathy,” Dr. Dubey says. “They not only provide information about the underlying etiology of neuropathy, they also point us towards if there’s an underlying cancer. They help us with having discussions with patients about the natural history of the disease and coming up with the best treatment regimen.”
The phenotype-specific approach to antibody evaluation is an improvement on previous approaches. All relevant antibodies are included, not just those associated with cancer, and an improved methodology for several important tests helps improve specificity.
“We are adapting our evaluations to the growing science behind antibody reporting, discovery, and utilization,” Dr. Dubey says. “We are trying to make sure that if a patient is presenting with one particular syndrome or predominant neurological phenotype, we are covering all potential autoantibodies that are paraneoplastic or autoimmune."
Listen to learn more about how comprehensive testing for autoimmune axonal neuropathies can provide clarity on a complicated condition.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 4 mL
Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.